Patents by Inventor Sharon T. Cload

Sharon T. Cload has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 11858979
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: January 2, 2024
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20210277089
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: February 16, 2021
    Publication date: September 9, 2021
    Inventors: Ray CAMPHAUSEN, Jonathan H. DAVIS, Sharon T. CLOAD, Fabienne M. DENHEZ, Amna SAEED-KOTHE, Dasa LIPOVSEK, Ching-Hsiung Frederick LO, Chee Meng LOW, Bowman MIAO, Tracy S. MITCHELL, Rex A. PARKER, Ginger C. RAKESTRAW, Katie A. RUSSO, Doree F. SITKOFF
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 10947297
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: March 16, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Serum albumin binding molecules
    Patent number: 10934572
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: March 2, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20190203248
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 4, 2019
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Serum albumin binding molecules
    Patent number: 10221438
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 5, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20180201665
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 19, 2018
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 9856309
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: January 2, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20170145464
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 29, 2016
    Publication date: May 25, 2017
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Serum albumin binding molecules
    Patent number: 9540424
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: January 10, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukerjee, Simeon I. Taylor
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9
    Publication number: 20160159883
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: December 2, 2015
    Publication date: June 9, 2016
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • Fibronectin based scaffold domain proteins that bind PCSK9
    Patent number: 9234027
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20150152147
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 4, 2015
    Inventors: Michael L. GOSSELIN, David FABRIZIO, Joanna F. SWAIN, Tracy MITCHELL, Ray CAMPHAUSEN, Sharon T. CLOAD, Eric FURFINE, Paul E. MORIN, Ranjan MUKHERJEE, Simeon I. TAYLOR
  • Serum albumin binding molecules
    Patent number: 8969289
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • Fibronectin based scaffold domain proteins that bind to PCSK9
    Patent number: 8420098
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: April 16, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO PCSK9
    Publication number: 20120094909
    Abstract: The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 19, 2012
    Inventors: Ray Camphausen, Jonathan H. Davis, Sharon T. Cload, Fabienne M. Denhez, Amna Saeed-Kothe, Dasa Lipovsek, Ching-Hsiung Frederick Lo, Chee Meng Low, Bowman Miao, Tracy S. Mitchell, Rex A. Parker, Ginger C. Rakestraw, Katie A. Russo, Doree F. Sitkoff
  • SERUM ALBUMIN BINDING MOLECULES
    Publication number: 20110305663
    Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: May 2, 2011
    Publication date: December 15, 2011
    Applicant: Bristol-Myers Squibb Company
    Inventors: Michael L. Gosselin, David Fabrizio, Joanna F. Swain, Tracy Mitchell, Ray Camphausen, Sharon T. Cload, Eric Furfine, Paul E. Morin, Ranjan Mukherjee, Simeon I. Taylor
  • Regulatable, catalytically active nucleic acids
    Publication number: 20040126882
    Abstract: Compositions and methods are provided to make, isolate, characterize and use regulatable, catalytically active nucleic acids (RCANA). The present invention is directed to RCANA that transduce molecular recognition into catalysis. Also, RCANAs according to the invention can be used as regulatory elements to control the expression of one or more genes in a metabolic pathway. RCANAs can also be used as regulated selectable markers to create a selective pressure favoring (or disfavoring) production of a targeted bioproduct.
    Type: Application
    Filed: September 24, 2002
    Publication date: July 1, 2004
    Inventors: Andrew D. Ellington, Jay Hesselberth, Kristin Thompson, Michael P. Robertson, Letha Sooter, Eric Davidson, J. Colin Cox, Timothy Riedel, Charles Wilson, Sharon T. Cload, Anthony D. Keefe
  • Compositions selective for adenosine diphosphate and methods of using same
    Publication number: 20040018515
    Abstract: Compositions which recognize and report on the concentration selectively adenosine diphosphate (ADP) and methods of making and using them are provided. The invention further relates to methods of using the compositions to monitor function of biological agents. Reagents and systems for performing the methods are also provided. The methods of the invention are useful in diagnostic applications and drug optimization.
    Type: Application
    Filed: April 2, 2003
    Publication date: January 29, 2004
    Inventors: John L. Diener, Jayaram Srinivasan, Nobuko Hamaguchi, Jill Blanchard, Jeffrey Kurz, Markus Kurz, Sharon T. Cload, David Epstein, Charles Wilson, Martin Stanton
  • Compositions selective for caffeine or aspartame and methods of using same
    Publication number: 20030228603
    Abstract: Compositions which recognize and report on the concentration of caffeine or aspartame target molecules. The invention further relates to methods of using the compositions to monitor the presence or concentration of such targets in a variety of samples, including those samples to be ingested, such as beverages, e.g., coffee or soft drinks.
    Type: Application
    Filed: April 3, 2003
    Publication date: December 11, 2003
    Inventors: Sharon T. Cload, Alicia Ferguson